Skip to content

Scientific Publications

Science

2025

Phase I Trial of TTI-101, a First-in-Class Oral Inhibitor of STAT3, in Patients with Advanced Solid Tumors

March 19, 2025

2024

The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer

February 14, 2024

A phase 1b/2 study to evaluate the safety and efficacy of TTI-101 as monotherapy and in combination in advanced hepatocellular carcinoma.

January 1, 2024

2023

Phase 1 trial evaluating TTI-101, a first-in-class, orally bioavailable, small molecule,
inhibitor of STAT3, in patients with advanced solid tumors.

June 1, 2023

Therapeutic Potential of a Small-Molecule STAT3 Inhibitor in a Mouse Model of Colitis

May 30, 2023

Aberrant function of pathogenic STAT3 mutant proteins is linked to altered stability of monomers and homodimers

March 23, 2023

KRAS-Mutant Lung Cancer: Targeting Molecular and Immunologic Pathways, Therapeutic Advantages and Restrictions

February 26, 2023

2022

Drugging “Undruggable” Disease-Causing Proteins: Focus on Signal Transducer and Activator of Transcription (STAT) 3

December 31, 2022

Genetic and Small-Molecule Modulation of Stat3 in a Mouse Model of Crohn’s Disease

November 28, 2022

2021

TTI-101: A Competitive Inhibitor of STAT3 that Spares Oxidative Phosphorylation and Reverses Mechanical Allodynia in Mouse Models of Neuropathic Pain

October 1, 2021

Analysis and Validation of Human Targets and Treatments Using a Hepatocellular Carcinoma–Immune Humanized Mouse Model

September 1, 2021

First-in-man phase I clinical trial evaluating TTI-101, an orally bioavailable, small molecule inhibitor of STAT3, in patients with advanced solid tumors

May 1, 2021

2020

Pharmacokinetics and pharmacodynamics of TTI-101, a STAT3 inhibitor that blocks muscle proteolysis in rats with chronic kidney disease

October 1, 2021

Stat3 activation induces insulin resistance via a muscle-specific E3 ubiquitin ligase Fbxo40

April 26, 2020

Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution

April 9, 2020

2018

Role of STAT3 in Skin Fibrosis and Transforming Growth Factor Beta Signalling

October 1, 2018

Contribution of STAT3 to Inflammatory and Fibrotic Diseases and Prospects for its Targeting for Treatment

August 5, 2018

2017

Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice

September 15, 2017

2016

STAT3 Inhibition Prevents Lung Inflammation, Remodeling, and Accumulation of Th2 and Th17 Cells in a Murine Asthma Model

December 1, 2016

STAT3 Inhibitors in Cancer: A Comprehensive Update

October 9, 2016

Diminution of Signal Transducer and Activator of Transcription 3 Signaling inhibits Vascular Permeability and Anaphylaxis

July 1, 2016

Small-molecule Inhibition of STAT3 in Radioresistant Head and Neck Squamous Cell Carcinoma

March 25, 2016

STAT-3 contributes to Pulmonary Fibrosis through Epithelial Injury and Fibroblast-Myofibroblast

January 1, 2016

2015

Small-molecule targeting of Signal Transducer and Activator of Transcription (STAT) 3 to treat Non-Small Cell Lung Cancer

November 1, 2015

Inhibition of STAT3 Activation Suppresses Caspase-3 and the Ubiquitin-Proteasome System, Leading to Preservation of Muscle Mass in Cancer Cachexia

April 24, 2015

2013

STAT3 Activation Links a C/EBPd to Myostatin Pathway to Stimulate Loss of Muscle Mass

September 3, 2013

2011

STAT3 Signaling in Acute Myeloid Leukemia: Ligand-dependent and -independent Activation and Induction of Apoptosis by a novel Small-molecule STAT3 Inhibitor

May 26, 2011

2009

Chemical Probes that competitively and selectively Inhibit STAT3 Activation

May 26, 2011

Scroll to Top

We use cookies to ensure that we give you the best experience on our website. By using this website you agree to the Privacy Policy and  Terms of Use.

Accept & Close